diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5999diaendo-5999Research ArticleСтатьиArticlesКлинико-фармакологические аспекты титирования дозировки метформинаKliniko-farmakologicheskie aspekty titirovaniya dozirovki metforminaКарповО ИKarpovO I-Институт фармакологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова, Санкт-Петербург200715092007103№3 (2007)5356Copyright © Карпов О.И., 20072007Карпов О.И.Karpov O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5999

Метформин относится к числу базовых средств для лечения сахарного диабета 2 типа (СД 2), а также, совместно с препаратами других групп применяется при метаболическом синдроме, ожирении, дислипидемиях, дизовариальных нарушениях и некоторых других состояниях. Фармако дина мические эффекты препарата, имеющие отношение к лечению СД 2, известные к настоящему времени, включают в себя: усиление утилизации глюкозы; увеличение числа рецепторов к инсулину на клеточной мембране и активизацию транспорта глюкозы в тканях; уменьшение продукции глюкозы печенью; уменьшение всасывания углеводов в желудочнокишечном тракте; увеличение потребления глюкозы мышечной и жировой тканями

метформинсахарный диабеттерапияReferencesCampbell A. Glycaemic control in type 2 diabetes // Clin Evid. - 2005;14:474-490.Campbell A. Glycaemic control in type 2 diabetes // Clin Evid. - 2005;14:474-490.Lord J.M., White S.I., Bailey C.J. et al. Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes // Br.Med.J. - 1983;286(6368):830-831.Lord J.M., White S.I., Bailey C.J. et al. Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes // Br.Med.J. - 1983;286(6368):830-831.Musi N., Goodyear L.J. Insulin resistance and improvements in signal transduction // Endocrine. - 2006;29(1):73-80.Musi N., Goodyear L.J. Insulin resistance and improvements in signal transduction // Endocrine. - 2006;29(1):73-80.Musi N. AMP-activated protein kinase and type 2 diabetes // Curr Med Chem. - 2006;13(5):583-589.Musi N. AMP-activated protein kinase and type 2 diabetes // Curr Med Chem. - 2006;13(5):583-589.Guigas B., Bertrand L., Taleux N. et al. 5-Aminoimidazole-4-carboxamide- 1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation // Diabetes. - 2006;55(4):865-74.Guigas B., Bertrand L., Taleux N. et al. 5-Aminoimidazole-4-carboxamide- 1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation // Diabetes. - 2006;55(4):865-74.Schumm-Draeger P.M. Current treatment with oral antidiabetic agents // MMW Fortschr Med. - 2006;148(9):33-35.Schumm-Draeger P.M. Current treatment with oral antidiabetic agents // MMW Fortschr Med. - 2006;148(9):33-35.Bailey C.J, Turner R.C. Metformin // N.Engl. J. Med. - 1996;334:574-579.Bailey C.J, Turner R.C. Metformin // N.Engl. J. Med. - 1996;334:574-579.Phillips S.A., Ciaraldi T.P., Kong A.P.S. et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy // Diabetes. - 2002;52:667-674. 9. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-18.Phillips S.A., Ciaraldi T.P., Kong A.P.S. et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy // Diabetes. - 2002;52:667-674. 9. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-18.Signore A., Fiore V., Chianelli M. et al. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes // Diabetes Res Clin Pract. - 1996;33(2):83-7.Signore A., Fiore V., Chianelli M. et al. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes // Diabetes Res Clin Pract. - 1996;33(2):83-7.Khan J.K., Pallaki M., Tolbert S.R., Hornick TR. Lactic acidemia associated with met-formin // Ann Pharmacother. - 2003;37(1):66-9.Khan J.K., Pallaki M., Tolbert S.R., Hornick TR. Lactic acidemia associated with met-formin // Ann Pharmacother. - 2003;37(1):66-9.Salpeter S.R., Greyber E., Pasternak G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163(21):2594-602.Salpeter S.R., Greyber E., Pasternak G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163(21):2594-602.Chan N.N., Brain H.P., Feher M.D. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999;16(4):273-81.Chan N.N., Brain H.P., Feher M.D. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999;16(4):273-81.http://www.mosbysdrugconsult.com/DrugConsult/ Top_200/Drugs/e3204.html#t003204-cp-1http://www.mosbysdrugconsult.com/DrugConsult/ Top_200/Drugs/e3204.html#t003204-cp-1De-Sheng Wang D-S., Jonker J.W, Kato Y. et al. Involvement of organic cation trans-porter 1 in hepatic and intestinal distribution of metformin // Prarmacol. Exp. Ther. - 2002;302(2):510-5De-Sheng Wang D-S., Jonker J.W, Kato Y. et al. Involvement of organic cation trans-porter 1 in hepatic and intestinal distribution of metformin // Prarmacol. Exp. Ther. - 2002;302(2):510-5Ikeda T., Iwata K., Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine // Biochem Pharmacol. - 2000;59(7):887-90.Ikeda T., Iwata K., Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine // Biochem Pharmacol. - 2000;59(7):887-90.Cheng A., George Fantus G. Oral antihyperglycemic therapy for type 2 diabetes melli-tus // CMAJ - 2005;172(2):213-26Cheng A., George Fantus G. Oral antihyperglycemic therapy for type 2 diabetes melli-tus // CMAJ - 2005;172(2):213-26McAnuff-Harding M.A., Omoruyi F.O., Asemota H.N. Intestinal disaccharidases and some renal enzymes in streptozotocin-induced diabetic rats // Life Sci. - 2006;78(22):2595-600.McAnuff-Harding M.A., Omoruyi F.O., Asemota H.N. Intestinal disaccharidases and some renal enzymes in streptozotocin-induced diabetic rats // Life Sci. - 2006;78(22):2595-600.Bretzke G. Diabetes mellitus and exocrine pancreas function // Z Gesamte Inn Med. - 1984;39(16):388-90.Bretzke G. Diabetes mellitus and exocrine pancreas function // Z Gesamte Inn Med. - 1984;39(16):388-90.Guarna M.M., Borowsky R.L. Genetically controlled food preference: biochemical mechanisms // Proc Natl Acad Sci USA. - 1993;90(11):5257-61.Guarna M.M., Borowsky R.L. Genetically controlled food preference: biochemical mechanisms // Proc Natl Acad Sci USA. - 1993;90(11):5257-61.Karpov O., Zaytsev A. Utilization of antimicrobials in CAP // Abstr. 5-th Annual In-tern. Meeting ISPOR, 2000, Arlington, USA. In:Value in Health.- 2000;3(2):124-125.Karpov O., Zaytsev A. Utilization of antimicrobials in CAP // Abstr. 5-th Annual In-tern. Meeting ISPOR, 2000, Arlington, USA. In:Value in Health.- 2000;3(2):124-125.Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29 (8): 1963-1972.Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29 (8): 1963-1972.

The authors declare that there are no conflicts of interest present.